The most common agents used in targeted therapy for CRC patients were anti‐EGFR (e.g., cetuximab) and anti‐VEGF/VEGFR agents (e.g., bevacizumab).3, 6. The gene discussed is VEGFA; the disease is colorectal carcinoma.